Equities

Shield Therapeutics PLC

STX:LSE

Shield Therapeutics PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)9.60
  • Today's Change-0.40 / -4.00%
  • Shares traded1.94m
  • 1 Year change209.68%
  • Beta2.7036
Data delayed at least 20 minutes, as of Feb 06 2026 16:01 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.

  • Revenue in GBP (TTM)30.49m
  • Net income in GBP-15.61m
  • Incorporated2015
  • Employees77.00
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Formosa Pharmaceuticals Inc282.85k-1.73m96.54m--96.54m--
T Man Pharmaceutical PCL54.89m10.48m98.87m960.0098.87m960.00
Shield Therapeutics PLC30.49m-15.61m101.90m77.00101.90m77.00
Transcenta Holding Ltd996.15k-28.20m101.93m171.00101.93m171.00
Fuso Pharmaceutical Industries Ltd289.93m-18.65m103.46m1.34k103.46m1.34k
Syncom Formulations (India) Ltd41.76m5.11m104.03m554.00104.03m554.00
Hester Biosciences Ltd25.49m3.32m104.12m562.00104.12m562.00
Jilin Provnc Hnn Chnglng Bio-pharm CoLtd98.15m19.37m107.97m798.00107.97m798.00
Data as of Feb 06 2026. Currency figures normalised to Shield Therapeutics PLC's reporting currency: UK Pound GBX

Institutional shareholders

23.31%Per cent of shares held by top holders
HolderShares% Held
UBS Asset Management Switzerland AGas of 03 Nov 202564.79m6.10%
Hargreaves Lansdown Asset Management Ltd.as of 23 Apr 202562.62m5.90%
Premier Fund Managers Ltd.as of 05 May 202330.00m2.83%
Hargreaves Lansdown Fund Managers Ltd.as of 03 Nov 202526.60m2.51%
Coutts & Co. (Private Banking)as of 03 Nov 202514.43m1.36%
Dowgate Capital Ltd.as of 03 Nov 202512.70m1.20%
Rahn+Bodmer Co.as of 03 Nov 202511.54m1.09%
IG Markets Ltd.as of 03 Nov 202510.83m1.02%
Killik & Co. LLPas of 05 May 202310.62m1.00%
Rathbones Investment Management Ltd.as of 03 Nov 20253.37m0.32%
More ▼
Data from 31 Mar 2025 - 22 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.